See more : Marin Software Incorporated (MRIN) Income Statement Analysis – Financial Results
Complete financial analysis of Nymox Pharmaceutical Corporation (NYMXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nymox Pharmaceutical Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mitsui E&S Holdings Co., Ltd. (MIESY) Income Statement Analysis – Financial Results
- Manomay Tex India Limited (MANOMAY.NS) Income Statement Analysis – Financial Results
- CENTR Brands Corp. (CNTRF) Income Statement Analysis – Financial Results
- tZERO Group, Inc. (TZROP) Income Statement Analysis – Financial Results
- Extra Space Storage Inc. (0IJV.L) Income Statement Analysis – Financial Results
Nymox Pharmaceutical Corporation (NYMXF)
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 5.00K | 116.00K | 299.00K | 224.00K | 284.00K |
| Cost of Revenue | 11.00K | 12.00K | 12.00K | 13.00K | 67.00K | 141.04K | 150.00K | 176.00K |
| Gross Profit | -11.00K | -12.00K | -12.00K | -8.00K | 49.00K | 157.96K | 74.00K | 108.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -160.00% | 42.24% | 52.83% | 33.04% | 38.03% |
| Research & Development | 3.98M | 3.76M | 6.65M | 8.11M | 7.37M | 6.67M | 7.87M | 6.80M |
| General & Administrative | 0.00 | 2.88M | 5.85M | 3.60M | 6.01M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.36M | 2.88M | 5.85M | 3.60M | 6.01M | 4.13M | 5.44M | 6.18M |
| Other Expenses | 0.00 | 113.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.34M | 6.64M | 12.49M | 11.71M | 13.37M | 10.80M | 13.31M | 12.98M |
| Cost & Expenses | 8.35M | 6.65M | 12.50M | 11.73M | 13.44M | 10.94M | 13.46M | 13.15M |
| Interest Income | 6.00K | 1.00K | 8.00K | 27.00K | 213.00K | 72.00K | 11.00K | 4.00K |
| Interest Expense | 61.00K | 43.00K | 39.00K | 42.00K | 38.00K | 18.00K | 204.00K | 234.00K |
| Depreciation & Amortization | 11.00K | 12.00K | 12.00K | 9.00K | 9.00K | 3.04K | 1.00K | 3.00K |
| EBITDA | -8.77M | -6.52M | -12.49M | -11.71M | -13.12M | -10.57M | -13.22M | -12.87M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -234,220.00% | -11,479.31% | -3,557.85% | -5,908.04% | -4,530.63% |
| Operating Income | -8.35M | -6.65M | -12.50M | -11.72M | -13.33M | -10.64M | -13.24M | -12.87M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -234,400.00% | -11,487.07% | -3,558.86% | -5,908.48% | -4,531.69% |
| Total Other Income/Expenses | -494.00K | 76.00K | -33.00K | -18.00K | 163.00K | 47.00K | -194.00K | -240.00K |
| Income Before Tax | -8.84M | -6.58M | -12.54M | -11.74M | -13.16M | -10.59M | -13.43M | -13.11M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -234,760.00% | -11,346.55% | -3,543.14% | -5,995.09% | -4,616.20% |
| Income Tax Expense | -433.00K | -1.00 | 0.00 | 0.00 | -1.00 | -2.00 | 0.00 | 0.00 |
| Net Income | -8.84M | -6.58M | -12.54M | -11.74M | -13.16M | -10.59M | -13.43M | -13.11M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -234,760.00% | -11,346.55% | -3,543.14% | -5,995.09% | -4,616.20% |
| EPS | -0.10 | -0.07 | -0.15 | -0.16 | -0.19 | -0.18 | -0.26 | -0.28 |
| EPS Diluted | -0.10 | -0.07 | -0.15 | -0.16 | -0.19 | -0.18 | -0.26 | -0.28 |
| Weighted Avg Shares Out | 91.69M | 89.38M | 81.98M | 73.82M | 68.85M | 60.47M | 52.65M | 46.16M |
| Weighted Avg Shares Out (Dil) | 91.69M | 89.38M | 81.98M | 73.82M | 68.85M | 60.47M | 52.65M | 46.16M |
Nymox Announces Filing of Annual Report
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on August 29, 2024.
Nymox Annual Report
IRVINE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld...
Nymox Required to Resubmit Application to DKMA
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run out of time and in order to continue will be required...
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal Order officially putting an end to the Bahamas litigation brought by...
Nymox December 27 Message to Shareholders
IRVINE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to provide this end-of-the year message to shareholders.
Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others
IRVINE, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has issued an order granting Nymox's preliminary injunction against Randall Lanham, Richard Cutler, Christopher Riley, and the Committee...
$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Court
IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has accepted on November 18, 2023 Nymox's lawsuit against AscellaHealth and issued a Summons to be served on Ascella. The...
Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million
IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- This week, Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) was forced to file a lawsuit in California Superior Court, Orange County, to protect its shareholders' interests, as Nymox alleges that a would-be...
NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized
IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) [OTC Markets---NYMXF] is pleased to announce that the Bahamian Court (Senior Justice Deborah Fraser) today issued an oral ruling suspending the Ex Parte Order of...
NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023
Ex-Employees and Agents, and those working in concert with them, are ordered by a California Court to stop using, disclosing, relying on, or otherwise make publicly available Nymox privileged information, and to return all Nymox material to the Company
Source: https://incomestatements.info
Category: Stock Reports